Skip to content

S. 2513 · 119th Congress (2025–2027)

OTC Monograph Drug User Fee Transparency Act

A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to transparency and reporting regarding over-the-counter drug monograph activities, and for other purposes.

CRS summary not yet available.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is S. 2513’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Tim Kaine (D-VA)
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jul 29, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. OTC Monograph Drug User Fee Transparency Act

    Display title, Short title · Introduced in Senate

  2. A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to transparency and reporting regarding over-the-counter drug monograph activities, and for other purposes.

    Official title · Introduced in Senate